Does cirrhotic cardiomyopathy exist? 50 years of uncertainty

Clinical Research in Cardiology

Volumn 102, Issue 12, 2013, Pages 859-864

  Pellicori, Pierpaolo ^a   Torromeo, Concetta ^b   Calicchia, Angela ^b   Ruffa, Alessandra ^b   Di Iorio, Martina ^b   Cleland, John G F ^a   Merli, Manuela ^b  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biomarkers; Cirrhotic cardiomyopathy; Diastolic heart failure; Review

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; CARDIAC GATED IMAGING; CARDIAC PATIENT; CARDIOMEGALY; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CIRRHOTIC CARDIOMYOPATHY; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT ATRIUM; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIVER CIRRHOSIS; NONHUMAN; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

ANIMALS; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; HUMANS; LIVER CIRRHOSIS;

EID: 84890560812     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-013-0610-1     Document Type: Review

References (65)

1. Møller S, Henriksen JH (2008) Cardiovascular complications of cirrhosis. Gut 57:268-278
2. Rayes N, Bechstein WO, Keck H, et al. (1995) Causes of death after liver transplantation: an analysis of 41 cases in 382 patients. Zentralblatt Chir 120:435-438
3. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L (2001) The cardiac response to exercise in cirrhosis. Gut 49:268-275
4. Kim MY, Baik SK, Won CS, et al. (2010) Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis. Korean J Hepatol 16:376-382
5. Zieve L (1958) Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis. Ann Intern Med 48:471-496
6. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011-1023
7. Kowalski HJ, Abelmann WH (1953) The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 32:1025-1033
8. Limas CJ, Guiha NH, Lekagul O, et al. (1974) Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 49:754-760
9. Merli M, Calicchia A, Ruffa A, et al. (2013) Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Eur J Intern Med 24:172-176
10. Ma Z, Lee SS (1996) Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 24:451-459
11. Møller S, Henriksen JH (2010) Cirrhotic cardiomyopathy. J Hepatol 53:179-190
12. Zardi EM, Abbate A, Zardi DM, et al. (2010) Cirrhotic cardiomyopathy. J Am Coll Cardiol 56:539-549
13. Lunseth JH, Olmstead EG, Abboud F (1958) A study of heart disease in one hundred eight hospitalized patients dying with portal cirrhosis. Arch Intern Med 102:405-413
14. Ortiz-Olvera NX, Castellanos-Pallares G, Gómez-Jiménez LM, et al. (2011) Anatomical cardiac alterations in liver cirrhosis: an autopsy study. Ann Hepatol 10:321-326
15. Bernardi M, Calandra S, Colantoni A, et al. (1998) Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27:28-34
16. Trevisani F, Merli M, Savelli F, et al. (2003) QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 38:461-467
17. Bal JS, Thuluvath PJ (2003) Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 23:243-248
18. Zambruni A, Trevisani F, Caraceni P, et al. (2006) Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 44:994-1002
19. Hansen S, Møller S, Bendtsen F, et al. (2007) Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. J Hepatol 47:373-380
20. Trevisani F, Di Micoli A, Zambruni A, et al. (2012) QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int 32:1510-1515
21. Wong F, Liu P, Lilly L, et al. (1999) Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 97:259-267
22. Torregrosa M, Aguadé S, Dos L, et al. (2005) Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 42(1):68-74
23. Kazankov K, Holland-Fischer P, Andersen NH, et al. (2011) Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int 31:534-540
24. Pozzi M, Carugo S, Boari G, et al. (1997) Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 26:1131-1137
25. Bansal S, Lindenfeld J, Schrier RW (2009) Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2:370-376
26. Pozzi M, Grassi G, Ratti L, et al. (2005) Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol 100:1110-1116
27. Merli M, Valeriano V, Funaro S, et al. (2002) Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 97:142-148
28. McMurray JJ, Adamopoulos S, Anker SD, et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803-869
29. Pitt B, Zannad F, Remme WJ, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717
30. Zannad F, McMurray JJ, Krum H, et al. (2011) EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11-21
31. Desai AS, Lewis EF, Li R, et al. (2011) Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 162:966-972
32. Rossi GP, Sacchetto A, Pavan E, et al. (1997) Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 95(6):1471-1478
33. Reil JC, Hohl M, Selejan S, et al. (2012) Aldosterone promotes atrial fibrillation. Eur Heart J 33(16):2098-2108
34. Pellicori P, Carubelli V, Zhang J, et al. (2013) IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging 6:16-28
35. Ayers CR, Davis JO, Lieberman F, et al. (1962) The effects of chronic hepatic venous congestion on the metabolism of d, l-aldosterone and d-aldosterone. J Clin Invest 41:884-895
36. Swedberg K, Komajda M, Böhm M, et al. (2010) SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875-885
37. Fox K, Ford I, Steg PG, BEAUTIFUL Investigators, et al. (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372(9641):807-816
38. Tan YT, Wenzelburger F, Lee E, et al. (2009) The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol 54:36-46
39. Nikitin NP, Witte KKA, Thackray SDR, et al. (2003) Longitudinal ventricular function: normal values of atrioventricular annular and myocardial velocities measured with color tissue Doppler imaging. J Am Soc Echo 16:906-921
40. Richand V, Lafitte S, Reant P, et al. (2007) An ultrasound speckle tracking (two-dimensional strain) analysis of myocardial deformation in professional soccer players compared with healthy subjects and hypertrophic cardiomyopathy. Am J Cardiol 100:128-132
41. Galderisi M, Lomoriello VS, Santoro A, et al. (2010) Differences of myocardial systolic deformation and correlates of diastolic function in competitive rowers and young hypertensives: a speckle-tracking echocardiography study. J Am Soc Echocardiogr 23:1190-1198
42. La Villa G, Romanelli RG, Casini Raggi V, et al. (1992) Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 16:156-161
43. Wong F, Siu S, Liu P, et al. (2001) Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci (Lond) 101:621-628
44. Henriksen JH, Gøtze JP, Fuglsang S, et al. (2003) Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 52:1511-1517
45. Pimenta J, Paulo C, Gomes A, et al. (2010) B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int 30:1059-1066
46. Vasatova M, Pudil R, Safka V, et al. (2013) Elevated cardiac markers are associated with higher mortality in patients after transjugular intrahepatic portosystemic shunt insertion. Ann Clin Biochem 50(Pt 2):122-126
47. Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 13:e17-e39
48. Sharma UC, Pokharel S, van Brakel TJ, et al. (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121-3128
49. Lin YH, Lin LY, Wu YW, et al. (2009) The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409:96-99
50. de Boer RA, Lok DJ, Jaarsma T, et al. (2011) Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43:60-68
51. de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. (2012) The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 272:55-64
52. Henderson NC, Mackinnon AC, Farnworth SL, et al. (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 103:5060-5065
53. Butscheid M, Hauptvogel P, Fritz P, et al. (2007) Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease. J Clin Pathol 60:415-418
54. Yilmaz Y, Eren F, Kurt R, et al. (2011) Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. Clin Biochem 44:955-958
55. Cheung KJ, Libbrecht L, Tilleman K, et al. (2010) Galectin-3-binding protein: a serological and histological assessment in accordance with hepatitis C-related liver fibrosis. Eur J Gastroenterol Hepatol 22:1066-1073
56. de Oliveira SA, de Freitas Souza BS, Sá Barreto EP, et al. (2012) Reduction of galectin-3 expression and liver fibrosis after cell therapy in a mouse model of cirrhosis. Cytotherapy 14:339-349
57. Wanninger J, Weigert J, Wiest R, et al. (2011) Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine 55:435-440
58. Cazzaniga M, Salerno F, Pagnozzi G, et al. (2007) Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 56:869-875
59. Rabie RN, Cazzaniga M, Salerno F, et al. (2009) The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 104:2458-2466
60. Krag A, Bendtsen F, Henriksen JH, et al. (2010) Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 59:105-110
61. Alexopoulou A, Papatheodoridis G, Pouriki S, et al. (2012) Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. Transpl Int 25:1174-1181
62. Nazar A, Guevara M, Sitges M, et al. (2013) Left ventricular function assessed by echocardiography in cirrhosis. Relationship to systemic hemodynamics and renal dysfunction. J Hepatol 58:51-57
63. Woo JJ, Koh YY, Kim HJ, et al. (2008) N-terminal pro B-type natriuretic peptide and the evaluation of cardiac dysfunction and severity of disease in cirrhotic patients. Yonsei Med J 49:625-631
64. Ziada D, Gaber R, Kotb N, et al. (2011) Predictive value of N-terminal pro B-type natriuretic peptide in tissue Doppler-diagnosed cirrhotic cardiomyopathy. Heart Mirror J 5:264-270
65. Enache I, Oswald-Mammosser M, Woehl-Jaegle ML, et al. (2013) Cirrhotic cardiomyopathy and hepatopulmonary syndrome: prevalence and prognosis in a series of patients. Respir Med 107:1030-1036